Veracyte | VCYT - Sales Revenues


Veracyte reported $150.32M in Sales Revenues for its fiscal quarter ending in June of 2026.





Sales Change Date
Agenus USD 33.7M 500K Mar/2026
Agilent USD 1.88B 43M Jun/2026
Anika Therapeutics USD 30.62M 2.8M Dec/2025
Arrowhead Research USD 75.23M 1.49M Jun/2026
Bruker USD 838.5M 15.1M Jun/2026
Heron Therapeutics USD 40.59M 2.38M Dec/2025
Illumina USD 1.16B 70M Jun/2026
Intrexon USD 717K 511K Jun/2024
Karyopharm Therapeutics USD 35.07M 987K Mar/2026
Laboratory Of America USD 3.73B 190M Jun/2026
Ligand Pharmaceuticals USD 83.7M 31.98M Jun/2026
Myriad Genetics USD 190.7M 9.7M Jun/2026
Rigel Pharmaceuticals USD 55.31M 18.47M Sep/2024
Roche Holding CHF 30.36B 14.71B Jun/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Siemens EUR 20.79B 1.03B Jun/2026
Sonic Healthcare AUD 5.42B 30M Jun/2026
Thermo Fisher Scientific USD 12.14B 147M Sep/2026
Veracyte USD 150.32M 11.25M Jun/2026
Waters USD 1.64B 370M Jun/2026